在神经退行性疾病中的血生物标志物的病理和认知相关物
Katheryn A Q Cousins1, Jeffrey S Phillips1, Sandhitsu R Das1
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
概括
血生物标志物,包括化陶氏181 (p-tau181),GFAP和NfL,可以准确检测阿尔茨海默病的病理学. 较高的NfL水平预测粉样蛋白阳性和粉样蛋白阴性个体的认知衰退速度更快.
科学领域:
- 神经学 神经学
- 生物标志物发现发现
- 神经退行性疾病 神经退行性疾病
背景情况:
- 血生物标志物是诊断神经退行性疾病的新兴工具.
- 准确检测阿尔茨海默病 (AD) 病理,特别是β-粉样蛋白 (Aβ) 状态,对于早期干预和研究至关重要.
- 现有的诊断方法可能是侵入性的或昂贵的,突出了需要可访问的替代品.
研究的目的:
- 为了研究血 fosforylated tau 181 (p-tau181),质纤维酸蛋白 (GFAP) 和神经纤维光链 (NfL) 的病理相关物.
- 评估这些等离子体生物标志物的诊断准确性,以区分Aβ+和Aβ-个体在一系列认知功能方面.
- 评估血生物标志物对认知衰退和疾病进展的预测价值.
主要方法:
- 招募了具有正常认知 (NormCog) 和受损认知 (ImpCog) 的参与者,分别为n=132和n=461.
- 使用脑脊液,正子辐射断层扫描或尸检确认了Aβ状态.
- 利用单分子阵列等离子体测量和物流回归与ROC分析来评估生物标志物性能;生存分析检查了临床痴呆症评级进展的时间.
主要成果:
- 结合p-tau181,GFAP和NfL的多变量模型在NormCog和ImpCog组中检测Aβ+状态时表现出高准确度 (ROCAUC = 0.87).
- 较高的血NfL水平显著预测了Aβ+ (HR=2.94) 和Aβ- (HR=3.11) 个体中临床痴呆症评级进展的更快.
- 血生物标志物显示出与tau PET和死后Aβ/tau病理学的独立关联.
结论:
- 结合血p-tau181,GFAP和NfL可显著提高神经退行性疾病中Aβ状态的诊断准确性.
- 血NfL是纵向认知衰退的强有力的预测因素,无论底层的Aβ病理.
- 这些发现支持了血生物标志物的实用性,以优化阿尔茨海默病病理学的检测和监测.
关键词:
与AD相关的痴呆症 (ADRD)阿尔茨海默氏症 (AD) 是一种疾病.认知能力下降 认知能力下降状纤维酸性蛋白质 (GFAP) 是一种神经纤维光链 (NfL) 是指神经纤维光链.酸化的181 (p-tau181) 是一种化181化合物.血生物标志物 血生物标志物更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
14:27Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
15.6K
相关概念视频
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
